Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 4 studies | 19% ± 3% | |
GABAergic neuron | 3 studies | 28% ± 5% | |
glutamatergic neuron | 3 studies | 37% ± 10% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 25% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 3289.05 | 258 / 258 | 100% | 25.77 | 230 / 230 |
brain | 99% | 2702.39 | 2612 / 2642 | 100% | 33.11 | 705 / 705 |
liver | 99% | 1466.71 | 223 / 226 | 98% | 10.39 | 399 / 406 |
kidney | 100% | 2021.07 | 89 / 89 | 95% | 15.87 | 857 / 901 |
skin | 91% | 1728.10 | 1643 / 1809 | 100% | 29.03 | 470 / 472 |
pancreas | 93% | 954.72 | 304 / 328 | 94% | 13.07 | 167 / 178 |
breast | 100% | 2520.36 | 458 / 459 | 86% | 6.99 | 958 / 1118 |
lung | 100% | 3689.63 | 577 / 578 | 79% | 6.40 | 914 / 1155 |
thymus | 98% | 1714.81 | 641 / 653 | 76% | 7.34 | 461 / 605 |
intestine | 100% | 3036.56 | 964 / 966 | 64% | 4.36 | 339 / 527 |
uterus | 99% | 4542.52 | 169 / 170 | 65% | 5.91 | 297 / 459 |
prostate | 99% | 2398.12 | 243 / 245 | 63% | 3.71 | 318 / 502 |
bladder | 100% | 3159.14 | 21 / 21 | 58% | 4.38 | 293 / 504 |
ovary | 100% | 3036.84 | 180 / 180 | 50% | 2.86 | 214 / 430 |
stomach | 76% | 1332.43 | 274 / 359 | 68% | 4.21 | 194 / 286 |
esophagus | 91% | 2439.52 | 1312 / 1445 | 48% | 2.52 | 88 / 183 |
adipose | 100% | 3565.93 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 19.10 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 25.80 | 29 / 29 |
spleen | 100% | 6870.34 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3859.10 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 1915.75 | 855 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 2429.57 | 912 / 929 | 0% | 0 | 0 / 0 |
muscle | 96% | 1587.53 | 769 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 76% | 5.58 | 34 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_1990166 | Biological process | protein localization to site of double-strand break |
GO_0006303 | Biological process | double-strand break repair via nonhomologous end joining |
GO_1990683 | Biological process | DNA double-strand break attachment to nuclear envelope |
GO_0016363 | Cellular component | nuclear matrix |
GO_0005654 | Cellular component | nucleoplasm |
GO_0035861 | Cellular component | site of double-strand break |
GO_0005637 | Cellular component | nuclear inner membrane |
GO_0005882 | Cellular component | intermediate filament |
GO_0005515 | Molecular function | protein binding |
Gene name | IFFO1 |
Protein name | Intermediate filament family orphan 1 IFFO1 protein Non-homologous end joining factor IFFO1 (NHEJ factor IFFO1) (Intermediate filament family orphan 1) (Tumor antigen HOM-TES-103) |
Synonyms | IFFO |
Description | FUNCTION: Nuclear matrix protein involved in the immobilization of broken DNA ends and the suppression of chromosome translocation during DNA double-strand breaks (DSBs) . Interacts with the nuclear lamina component LMNA, resulting in the formation of a nucleoskeleton that relocalizes to the DSB sites in a XRCC4-dependent manner and promotes the immobilization of the broken ends, thereby preventing chromosome translocation . Acts as a scaffold that allows the DNA repair protein XRCC4 and LMNA to assemble into a complex at the DSB sites . . |
Accessions | ENST00000356896.8 [Q0D2I5-5] A0A087WZ16 ENST00000396840.6 [Q0D2I5-1] ENST00000465801.5 E9PPX7 ENST00000336604.8 [Q0D2I5-4] Q6P593 ENST00000619571.5 Q0D2I5 ENST00000487279.6 [Q0D2I5-3] |